Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients
ANZDATA
Article
- Posted15 Apr 2010
- PMID20470309
Periodical/sNephrology (Carlton)
